Drug discovery: a historical perspective.

  title={Drug discovery: a historical perspective.},
  author={J{\"u}rgen Dr. Drews},
  volume={287 5460},
  • J. Drews
  • Published 17 March 2000
  • Biology
  • Science
Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the… 
Drug Discovery: An In Silico Approach
This chapter explains the computer-aided drug discovery protocols classified on the basis of availability of information for the target in question, thereby revealing more suitable targets for designing future medicines and increasing therapeutic options.
HTS in the new millennium: the role of pharmacology and flexibility.
Stategic trends in the drug industry.
Genome Sequencing and Genomic Technologies in Drug Discovery and Development
The attrition rate of the drug discovery and development pipeline continues to be a major problem, as highlighted by the large number of compounds that fail in clinical trials because of poor pharmacology, toxicity, and/or lack of efficacy.
The Future for Genomic Medicine in Inflammatory Diseases
This chapter looks through the relatively short history of applying Antisense, RNA interference, gene therapy, and microRNAs in different disease areas and how each technology rose and fell out of favor after significant investment; looks at the current state of the field and how out of this body of work the future looks brighter.
Drug discovery processes to drug targeting mechanisms
The review will describe the preclinical stages, identification and validation of target through HTS (high throughput screening assay) and finally approval of drug molecule for further clinical development.
Review of approaches from drug discovery process to drug targeting mechanisms
The review will describe the preclinical stages, identification, and validation of target through HTS (high throughput screening assay) and finally approval of drug molecule for further clinical development.
Role of Medicinal Chemist in the Modern Drug Discovery and
The previous era of modern drug discovery was dominated by chemistry, whereas now a more rational approach is employed where knowledge about enzymes and receptors has required a unique dialogue between chemists and biologists.
This review intends to present a comprehensive view of overall transition and modernization of the drug discovery process and it’s impacts on the scientific community.


Structural genomics: beyond the Human Genome Project
A program of high-throughput X-ray crystallography aimed at developing a comprehensive mechanistic understanding of normal and abnormal human and microbial physiology at the molecular level is about to embark on.
Antibody phage display technology and its applications.
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Clinicians who frequently face difficult decisions about dosage should be aware that the book closes with an 80-page table of pharmacokinetic data relevant to dosage adjustment, and the editors clearly see clinicians and clinicians-to-be as their main audience, andThe text reflects this.
Pharmacological rescue of mutant p53 conformation and function.
Small synthetic molecules identified promoted the stability of wild-type p53 but also allowed mutant p53 to maintain an active conformation, enabling it to activate transcription and to slow tumor growth in mice.
The molecular basis for growth hormone-receptor interactions.
Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A.
Compounds that interfere selectively with the calcineurin-NFAT interaction without affecting calcineURin phosphatase activity may be useful as therapeutic agents that are less toxic than current drugs.
Bioactive Diversity and Screening Library Selection via Affinity Fingerprinting
It is demonstrated how affinity fingerprints may be used in conjunction with simple algorithms to select active-enriched diverse training sets and to efficiently extract the most active compounds from a large library.
A humanized antibody that binds to the interleukin 2 receptor.
A "humanized" antibody is constructed by combining the complementarity-determining regions (CDRs) of the anti-Tac antibody with human framework and constant regions and has an affinity for p55 of 3 x 10(9) M-1, about 1/3 that of murine anti- Tac.
Designed molecules that fold to mimic protein secondary structures.